Compare Lockheed Martin Corporation (LMT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs TransMedics Group Inc — how do they compare? Lockheed Martin Corporation trades at $598.94 (market cap $137.96B), while TransMedics Group Inc trades at $86.79 (market cap $3.10B). The key difference: Lockheed Martin Corporation is far larger — about 44.5× TransMedics Group Inc's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| LMT | TMDX | |
|---|---|---|
Market Cap | $137.96B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $676.70 | $150.42 |
52-Week Low | $431.56 | $61.99 |
Enterprise Value | $154.71B | $3.49B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $603.16, up 2.59% with strong technical momentum and bullish moving averages. The company reported mixed Q2 2026 earnings with a beat on EPS but faces margin pressure with net income margin declining to 8.16%. Recent news highlights major defense contracts including a $53.9 billion Patriot missile order and successful testing of next-generation interceptors, supporting the record $230 billion backlog.
Outlook remains positive with analyst consensus at Buy (56.76%) and $608 price target, though risks include execution on massive backlog and margin sustainability. The stock offers steady dividends ($3.45 quarterly) and benefits from elevated defense spending, but valuation multiples (P/E 22.04) require continued earnings growth to justify upside.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
